APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

01 Mar 2023 07:00:02 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares

27 Feb 2023 17:19:35 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

22 Feb 2023 21:48:09 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

22 Feb 2023 07:22:35 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

21 Feb 2023 16:14:10 By Nasdaq GlobeNewswire

FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness

17 Feb 2023 16:06:06 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

05 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy

16 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

22 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

18 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results

07 Nov 2022 16:05:02 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)

03 Nov 2022 16:01:01 By Nasdaq GlobeNewswire

Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting

03 Nov 2022 09:05:00 By Nasdaq GlobeNewswire